According to Zacks, “Although Gilead’s fourth quarter results beat on both earnings and sales, the guidance for 2017 was disappointing. The HCV franchise continues to be under competitive and pricing pressure due to which the sales of Harvoni and Sovaldi have declined. Total HCV treatment starts in the U.S. were an estimated 231,000 in 2016, approximately 25,000 less than 2015. The company expects a further decline in patients starts in 2017. In addition, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. Shares of Gilead have underperformed the biotech industry in the past one year. On a positive note, Epclusa’s uptake has been encouraging while the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.”
Zacks Investment Research lowered shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a hold rating to a sell rating in a report issued on Monday.
Several other research firms also recently weighed in on GILD. Stifel Nicolaus began coverage on Gilead Sciences in a research note on Monday, November 14th. They set a buy rating and a $100.00 price target on the stock. They noted that the move was a valuation call. Vetr downgraded Gilead Sciences from a strong-buy rating to a buy rating and set a $84.73 target price on the stock. in a research note on Wednesday, January 4th. Leerink Swann restated a market perform rating and issued a $89.00 target price on shares of Gilead Sciences in a research note on Tuesday, November 15th. Cowen and Company restated a buy rating and issued a $100.00 target price on shares of Gilead Sciences in a research note on Friday, January 6th. Finally, William Blair restated an outperform rating on shares of Gilead Sciences in a research note on Wednesday, October 26th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences has a consensus rating of Buy and an average price target of $88.94.
Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.57% during midday trading on Monday, reaching $66.74. The company had a trading volume of 1,457,351 shares. The stock has a market capitalization of $87.43 billion, a price-to-earnings ratio of 6.71 and a beta of 1.11. The firm’s 50 day moving average price is $72.26 and its 200-day moving average price is $75.71. Gilead Sciences has a 1-year low of $65.38 and a 1-year high of $103.10.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.61 by $0.09. The business had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $7.16 billion. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The company’s quarterly revenue was down 13.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.32 EPS. Equities research analysts expect that Gilead Sciences will post $8.88 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th will be paid a $0.52 dividend. The ex-dividend date is Tuesday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 dividend on an annualized basis and a yield of 3.13%. Gilead Sciences’s dividend payout ratio (DPR) is currently 18.91%.
In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00. Following the sale, the director now directly owns 121,761 shares in the company, valued at $9,115,028.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the sale, the insider now owns 3,204,433 shares in the company, valued at $235,814,224.47. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of GILD. Van Hulzen Asset Management LLC boosted its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares during the period. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 774 shares during the period. Gemmer Asset Management LLC boosted its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares during the period. Lombard Odier Transatlantic Limited Partnership boosted its stake in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 500 shares during the period. Finally, Roble Belko & Company Inc boosted its stake in Gilead Sciences by 19.9% in the third quarter. Roble Belko & Company Inc now owns 1,605 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 266 shares during the period. Institutional investors and hedge funds own 74.19% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Get a free copy of the Zacks research report on Gilead Sciences (GILD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com